Skip to content
Back to meeting Original
Dr Amol Akhade· @SuyogCancer · X·· 1 day agoScore70
Body

Saffron trial. Osimertinib plus savolitinib against chemo, post progression on osimertinib for advanced NSCLC with egfr mutation and met amplification /overexpression. @OncoAlert @myESMO #esmo26

117 views · 0 likes · 0 reposts · 0 replies

Source: Dr Amol Akhade · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.